IMUNON announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses. The NOL sales are administered through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer (NOL) program. This non-dilutive funding further strengthens the Company’s balance sheet.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
- IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
- Imunon timelines unchanged despite CEO departure, says H.C. Wainwright
- Imunon files IND application to begin human testing of IMNN-101
- Imunon Announces CEO Resignation and Interim Leadership Transition